Ultimately, this work provides a compelling argument for BDNF-based therapies as a promising avenue for mitigating the cognitive decline associated with Alzheimer’s disease, signaling a hopeful direction for future research and clinical trials. Here, BDNF is linked to early-onset autosomal dominant Alzheimer disease.